This may have something to do with it:
Mesoblast (NASDAQ:MESO) was downgraded by Chardan Capital to a "sell" rating in a research note issued to investors on Friday, Stock Target Advisor reports. They currently have a $7.50 price target on the stock, up from their previous price target of $5.50. Chardan Capital's target price indicates a potential downside of 52.35% from the stock's current price.
MESO Nasdaq update, page-1535
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
0.030(1.90%) |
Mkt cap ! $1.832B | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.65 | $1.59 | $7.014M | 4.343M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 342 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.61 | 54534 | 8 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |